

Ivermectin / Abamectin Liquid Formulation

Version 6.8 Revision Date: 30.09.2023 SDS Number: 1209999-00023 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

SECTION 1: IDENTIFICATION

Product name : Ivermectin / Abamectin Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 91-105 Harpin Street
Bendigo 3550, Victoria Australia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Acute toxicity (Oral) : Category 4

Acute toxicity (Inhalation) : Category 4

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)


Specific target organ toxicity - single exposure : Category 3

Specific target organ toxicity - repeated exposure : Category 2 (Central nervous system)

GHS label elements

Ivermectin / Abamectin Liquid Formulation

Version 6.8 Revision Date: 30.09.2023 SDS Number: 1209999-00023 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

- Hazard pictograms : 
- Signal word : Danger
- Hazard statements : H302 + H332 Harmful if swallowed or if inhaled.
 H315 Causes skin irritation.
 H319 Causes serious eye irritation.
 H335 May cause respiratory irritation.
 H360D May damage the unborn child.
 H371 May cause damage to organs (Central nervous system) if swallowed.
 H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.
- Precautionary statements : **Prevention:**
 P201 Obtain special instructions before use.
 P202 Do not handle until all safety precautions have been read and understood.
 P260 Do not breathe mist or vapours.
 P264 Wash skin thoroughly after handling.
 P270 Do not eat, drink or smoke when using this product.
 P271 Use only outdoors or in a well-ventilated area.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
- Response:**
 P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
 P302 + P352 IF ON SKIN: Wash with plenty of water.
 P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
 P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
 P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
 P332 + P313 If skin irritation occurs: Get medical advice/ attention.
 P337 + P313 If eye irritation persists: Get medical advice/ attention.
- Storage:**
 P405 Store locked up.
- Disposal:**
 P501 Dispose of contents/ container to an approved waste disposal plant.

Ivermectin / Abamectin Liquid Formulation

Version 6.8 Revision Date: 30.09.2023 SDS Number: 1209999-00023 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Corn oil	8001-30-7	>= 10 -< 30
N-Methyl-2-pyrrolidone	872-50-4	>= 20 -< 30
Ivermectin	70288-86-7	>= 1 -< 10
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	>= 1 -< 3
(dl)-a-Tocopheryl acetate	7695-91-2	< 10

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Harmful if swallowed or if inhaled.
Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
May damage the unborn child.
May cause damage to organs if swallowed.
May cause damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Notes to physician : when the potential for exposure exists (see section 8).
: Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Hazchem Code : •3Z

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Ivermectin / Abamectin Liquid Formulation

Version 6.8 Revision Date: 30.09.2023 SDS Number: 1209999-00023 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
 Do not breathe mist or vapours.
 Do not swallow.
 Do not get in eyes.
 Wash skin thoroughly after handling.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Keep container tightly closed.
 Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
 Do not eat, drink or smoke when using this product.
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
 When using do not eat, drink or smoke.
 Wash contaminated clothing before re-use.
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
 Store locked up.
 Keep tightly closed.
 Keep in a cool, well-ventilated place.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Corn oil	8001-30-7	TWA (Mist)	10 mg/m ³	AU OEL
N-Methyl-2-pyrrolidone	872-50-4	TWA	25 ppm 103 mg/m ³	AU OEL
Further information: Skin absorption				

Ivermectin / Abamectin Liquid Formulation

Version 6.8 Revision Date: 30.09.2023 SDS Number: 1209999-00023 Date of last issue: 04.04.2023
 Date of first issue: 10.01.2017

		STEL	75 ppm 309 mg/m ³	AU OEL
Further information: Skin absorption				
Ivermectin	70288-86-7	TWA	30 µg/m ³ (OEB 3)	Internal
Further information: Skin				
		Wipe limit	300 µg/100 cm ²	Internal
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 µg/m ³ (OEB 3)	Internal
		Wipe limit	150 µg/100 cm ²	Internal
(dl)-a-Tocopheryl acetate	7695-91-2	TWA	5000 µg/m ³ (OEB 1)	Internal

Biological occupational exposure limits

Components	CAS-No.	Control parameters	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

Ivermectin / Abamectin Liquid Formulation

Version 6.8 Revision Date: 30.09.2023 SDS Number: 1209999-00023 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

Skin and body protection : aerosols.
: Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Colour : light yellow

Odour : characteristic

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : > 100 °C

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 0.91 - 1.00 mg/l

Solubility(ies)
Water solubility : insoluble

Partition coefficient: n-octanol/water : Not applicable

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed or if inhaled.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,031 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 1.84 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Ivermectin / Abamectin Liquid Formulation

Version 6.8 Revision Date: 30.09.2023 SDS Number: 1209999-00023 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

Components:**Corn oil:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 401
Remarks: Based on data from similar materials

N-Methyl-2-pyrrolidone:

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg
LD50 (Mouse): 10 mg/kg
LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2,000 mg/kg

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

(dl)-a-Tocopheryl acetate:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 3,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Causes skin irritation.

Components:**Corn oil:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

N-Methyl-2-pyrrolidone:

Result : Skin irritation

Ivermectin:

Species : Rabbit
Result : No skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit
Result : No skin irritation

(dl)-a-Tocopheryl acetate:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**Corn oil:**

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405
Remarks : Based on data from similar materials

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

N-Methyl-2-pyrrolidone:

Species	: Rabbit
Result	: Irritation to eyes, reversing within 21 days

Ivermectin:

Species	: Rabbit
Result	: Mild eye irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	: Rabbit
Result	: Mild eye irritation

(dl)-a-Tocopheryl acetate:

Species	: Rabbit
Result	: No eye irritation
Method	: OECD Test Guideline 405

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Corn oil:**

Test Type	: Human repeat insult patch test (HRIPT)
Exposure routes	: Skin contact
Result	: negative

N-Methyl-2-pyrrolidone:

Test Type	: Local lymph node assay (LLNA)
Exposure routes	: Skin contact
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: negative
Remarks	: Based on data from similar materials

Ivermectin:

Exposure routes	: Dermal
Species	: Humans
Result	: Does not cause skin sensitisation.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type	: Maximisation Test
Exposure routes	: Skin contact

Ivermectin / Abamectin Liquid Formulation

Version 6.8 Revision Date: 30.09.2023 SDS Number: 1209999-00023 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

Result : Not a skin sensitizer.

(dl)-a-Tocopheryl acetate:

Test Type : Draize Test
Exposure routes : Skin contact
Species : Humans
Result : negative

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Corn oil:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

N-Methyl-2-pyrrolidone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 474
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Hamster
Application Route: Ingestion
Method: OECD Test Guideline 475
Result: negative

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: negative

Test Type: Mouse Lymphoma
Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

(dl)-a-Tocopheryl acetate:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Species : Rat
 Application Route : inhalation (vapour)
 Exposure time : 2 Years
 Result : negative

Ivermectin:

Species : Rat
 Application Route : Oral
 NOAEL : 1.5 mg/kg body weight
 Result : negative
 Remarks : Based on data from similar materials

Species : Mouse
 Application Route : Oral
 NOAEL : 2.0 mg/kg body weight
 Result : negative
 Remarks : Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
 Application Route : Oral
 Exposure time : 105 weeks
 Result : negative

Species : Mouse
 Application Route : Oral
 Exposure time : 93 weeks
 Result : negative

(dl)-a-Tocopheryl acetate:

Species : Rat
 Application Route : Ingestion
 Exposure time : 104 weeks
 Result : negative

Reproductive toxicity

May damage the unborn child.

Components:**N-Methyl-2-pyrrolidone:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Method: OECD Test Guideline 416
 Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Ingestion

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Method: OECD Test Guideline 414
Result: positive

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapour)
Result: positive

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Result: positive

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Ivermectin:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: NOAEL: 0.12 mg/kg body weight

Result: Fetotoxicity

Effects on foetal development

: Test Type: Embryo-foetal development

Species: Mouse

Application Route: Oral

General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight

Developmental Toxicity: NOAEL: 0.2 mg/kg body weight

Result: Cleft palate

Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: LOAEL: 2 mg/kg body weight

Result: Cleft palate, Teratogenic effects, Reduced embryonic survival

Remarks: Adverse developmental effects were observed

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 1.6 mg/kg body weight

Result: Teratogenic effects

Reproductive toxicity - Assessment

: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

(dl)-a-Tocopheryl acetate:

Effects on fertility

: Test Type: Reproduction/Developmental toxicity screening test

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal development

: Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion

Result: negative

STOT - single exposure

May cause respiratory irritation.

May cause damage to organs (Central nervous system) if swallowed.

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Components:**N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

Ivermectin:

Target Organs : Central nervous system
 Assessment : Causes damage to organs.

STOT - repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:**Ivermectin:**

Target Organs : Central nervous system
 Assessment : Causes damage to organs through prolonged or repeated exposure.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes : Ingestion
 Target Organs : Central nervous system
 Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Corn oil:**

Species : Rat
 NOAEL : > 300 mg/kg
 Application Route : Ingestion
 Exposure time : 28 Days
 Remarks : Based on data from similar materials

N-Methyl-2-pyrrolidone:

Species : Rat, male
 NOAEL : 169 mg/kg
 LOAEL : 433 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days
 Method : OECD Test Guideline 408

Species : Rat
 NOAEL : 0.5 mg/l
 LOAEL : 1 mg/l
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 96 Days

Ivermectin / Abamectin Liquid Formulation

Version 6.8 Revision Date: 30.09.2023 SDS Number: 1209999-00023 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

Method : OECD Test Guideline 413

Species : Rabbit
NOAEL : 826 mg/kg
LOAEL : 1,653 mg/kg
Application Route : Skin contact
Exposure time : 20 Days

Ivermectin:

Species : Dog
NOAEL : 0.5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system
Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1.2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 0.4 mg/kg
LOAEL : 0.8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : spleen, Bone marrow, Kidney

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
NOAEL : 1.5 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Mouse
NOAEL : 4.0 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Dog
NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Central nervous system

Ivermectin / Abamectin Liquid Formulation

Version 6.8 Revision Date: 30.09.2023 SDS Number: 1209999-00023 Date of last issue: 04.04.2023
Date of first issue: 10.01.2017

Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system

(dl)-a-Tocopheryl acetate:

Species : Rat
NOAEL : 500 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****N-Methyl-2-pyrrolidone:**

Skin contact : Symptoms: Skin irritation

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.
Eye contact : Remarks: May irritate eyes.
Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion : Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Corn oil:**

Toxicity to fish : LL50 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h
Method: ISO 7346/1
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Toxicity to algae/aquatic plants : EL50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: Directive 67/548/EEC, Annex V, C.3.
 Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOELR (Daphnia magna (Water flea)): > 1 mg/l
 Exposure time: 21 d
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 211
 Remarks: Based on data from similar materials

N-Methyl-2-pyrrolidone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
 Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
 Exposure time: 24 h
 Method: DIN 38412

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l
 Exposure time: 72 h
 EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l
 Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 12.5 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 600 mg/l
 Exposure time: 30 min
 Method: ISO 8192

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
 Exposure time: 96 h
 LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
 Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
 Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
 Exposure time: 96 h
- LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
 Exposure time: 96 h
- LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
 Exposure time: 96 h
- LC50 (Cyprinus carpio (Carp)): 42 µg/l
 Exposure time: 96 h
- LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
 Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 0.022 µg/l
 Exposure time: 96 h
- EC50 (Daphnia magna (Water flea)): 0.34 µg/l
 Exposure time: 48 h
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
 Exposure time: 72 h
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l
 Exposure time: 32 d
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.03 µg/l
 Exposure time: 21 d
- NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l
 Exposure time: 28 d
- Toxicity to microorganisms : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition

(dl)-a-Tocopheryl acetate:

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l
Exposure time: 28 d

Toxicity to microorganisms : EC50: > 927 mg/l
Exposure time: 30 min
Method: ISO 8192

Persistence and degradability**Components:****Corn oil:**

Biodegradability : Result: Readily biodegradable.
Remarks: Based on data from similar materials

N-Methyl-2-pyrrolidone:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Ivermectin:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

(dl)-a-Tocopheryl acetate:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 21.7 - 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Bioaccumulative potential**Components:****Corn oil:**

Partition coefficient: n-octanol/water : log Pow: > 4
Method: OECD Test Guideline 117

N-Methyl-2-pyrrolidone:

Partition coefficient: n-octanol/water : log Pow: -0.46
Method: OECD Test Guideline 107

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

Mobility in soil**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environmental compartments : log Koc: > 3.6

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**ADG**

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
Hazchem Code : •3Z
Environmentally hazardous : yes

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

The components of this product are reported in the following inventories:

AICS : not determined
 DSL : not determined
 IECSC : not determined

SECTION 16: ANY OTHER RELEVANT INFORMATION**Further information**

Revision Date : 30.09.2023
 Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)
 AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

AU OEL / TWA : Exposure standard - time weighted average
 AU OEL / STEL : Exposure standard - short term exposure limit

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory con-

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.8	30.09.2023	1209999-00023	Date of first issue: 10.01.2017

centration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN